The hyperphosphorylation of tau is consistently observed in secondary tauopathies, such as chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), and Alzheimer’s disease (AD; Edwards et al., 2017; Johnson et al., 2017; Rubenstein et al., 2017; VanItallie, 2019), and is regarded as a risk factor for AD and CTE (Washington et al., 2016; Collins-Praino and Corrigan, 2017; Kulbe and Hall, 2017). The gene discussed is MAPT; the disease is Alzheimer disease.